NCT04936529 2026-03-13
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
141 trialsNCT06254326 2026-03-09
ADAGiO
University of Florida
Phase 1 Active not recruiting
NCT04144023 2026-03-05
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Mayo Clinic
Phase 1 Recruiting
NCT06528496 2026-02-10
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03334305 2026-01-29
ACTION
University of Florida
Phase 1 Terminated
NCT07377435 2026-01-29
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Beth Israel Deaconess Medical Center
Phase 1 Not yet recruiting
NCT07374029 2026-01-28
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Beth Israel Deaconess Medical Center
Phase 1 Not yet recruiting
NCT05544968 2026-01-12
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT07327411 2026-01-08
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT01757626 2026-01-07
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT06514898 2025-12-18
MATCHPOINT
University of Florida
Phase 1 Active not recruiting
NCT05307835 2025-12-02
Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Active not recruiting
NCT06626516 2025-11-28
Tebentafusp-tebn With LDT in Metastatic UM
Thomas Jefferson University
Phase 1/2 Recruiting
NCT01857934 2025-11-17
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT06450041 2025-11-04
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Recruiting
NCT04237623 2025-10-30
GM-CSF With Post-Transplant Cyclophosphamide
Northside Hospital, Inc.
Phase 2 Recruiting
NCT03396575 2025-10-29
BRAVO
University of Florida
Phase 1 Terminated
NCT02502786 2025-10-07
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03033303 2025-10-07
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04963413 2025-08-06
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
University of Florida
Phase 1 Terminated
NCT06651853 2025-07-23
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT03189706 2025-07-02
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06013618 2025-06-17
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase 2 Recruiting
NCT04040231 2025-05-13
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00436254 2025-04-06
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
University of Washington
Phase 1 Completed
NCT02465268 2025-01-14
ATTAC-II
University of Florida
Phase 2 Completed
NCT04856176 2025-01-01
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Tufts Medical Center
Phase 2 Terminated
NCT04013672 2024-08-28
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Case Comprehensive Cancer Center
Phase 2 Completed
NCT04739618 2024-07-23
Metastatic Solid Cancer Clinical Trial
ImmunSYS, LLC
Phase 2 Active not recruiting
NCT06472739 2024-06-25
The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy
Sun Yat-sen University
Phase 2 Recruiting
NCT00799110 2024-06-11
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT02169609 2024-04-22
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Phase 2 Completed
NCT05817214 2024-04-19
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Zhongnan Hospital
Phase 2 Recruiting
NCT03927222 2024-04-08
I-ATTAC
Duke University
Phase 2 Terminated
NCT04408092 2024-03-15
Study of the Effect of GM-CSF on Macrophages in Ependymoma
University of Colorado, Denver
Phase EARLY_PHASE1 Completed
NCT06047860 2023-09-21
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT03113851 2023-06-13
Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2 Completed
NCT04703426 2023-05-22
Sargramostim (GM-CSF) + PD-1
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT05790447 2023-03-30
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05760196 2023-03-08
Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors
Renmin Hospital of Wuhan University
Phase 2 Unknown
NCT02641782 2022-11-04
NB2013-HR
University of Cologne
Phase 2 Terminated
NCT05603013 2022-11-02
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT01700673 2022-10-18
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00070070 2022-10-12
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT05530200 2022-09-07
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT01064375 2022-08-19
El-porCEA
Karolinska University Hospital
Phase 1/2 Completed
NCT04892498 2022-08-09
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT01673217 2022-08-01
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT05407649 2022-06-07
Abscopal Effect of Radiotherapy in Combination With rhGM-CSF for Advanced Thymic Epithelial Tumours
Shanghai Cancer Hospital, China
Phase 2 Unknown
NCT05292417 2022-03-31
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
The First Affiliated Hospital of Xiamen University
Phase 2 Unknown